William Blair Has Negative Forecast for Incyte Q2 Earnings

Incyte Corporation (NASDAQ:INCY - Free Report) - Equities research analysts at William Blair dropped their Q2 2025 earnings per share (EPS) estimates for Incyte in a research note issued on Monday, July 14th. William Blair analyst M. Phipps now anticipates that the biopharmaceutical company will post earnings of $1.06 per share for the quarter, down from their prior estimate of $1.11. William Blair currently has a "Market Perform" rating on the stock. The consensus estimate for Incyte's current full-year earnings is $4.86 per share. William Blair also issued estimates for Incyte's FY2025 earnings at $4.55 EPS and FY2026 earnings at $5.75 EPS.

Several other equities analysts have also recently issued reports on INCY. Wall Street Zen upgraded Incyte from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, April 30th. Citigroup restated a "buy" rating on shares of Incyte in a research report on Tuesday, June 3rd. Royal Bank Of Canada set a $67.00 price objective on Incyte and gave the company a "sector perform" rating in a report on Monday, June 23rd. Morgan Stanley lowered their price objective on Incyte from $69.00 to $65.00 and set an "equal weight" rating on the stock in a report on Monday, March 24th. Finally, JPMorgan Chase & Co. lowered their price objective on Incyte from $68.00 to $67.00 and set a "neutral" rating on the stock in a report on Monday. One analyst has rated the stock with a sell rating, twelve have given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Incyte currently has an average rating of "Hold" and an average target price of $74.47.

Incyte Stock Performance

INCY stock traded up $0.98 during trading on Tuesday, hitting $69.23. The company had a trading volume of 1,026,555 shares, compared to its average volume of 1,948,516. The firm has a market cap of $13.40 billion, a PE ratio of 216.35, a price-to-earnings-growth ratio of 0.57 and a beta of 0.68. Incyte has a 1-year low of $53.56 and a 1-year high of $83.95. The firm has a 50-day moving average price of $66.75 and a 200-day moving average price of $66.65. The company has a quick ratio of 2.00, a current ratio of 2.04 and a debt-to-equity ratio of 0.01.

Incyte (NASDAQ:INCY - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $1.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.01 by $0.15. The firm had revenue of $1.05 billion for the quarter, compared to analysts' expectations of $996.17 million. Incyte had a return on equity of 2.77% and a net margin of 0.48%. The firm's revenue for the quarter was up 19.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.64 EPS.

Institutional Trading of Incyte

A number of institutional investors and hedge funds have recently made changes to their positions in INCY. Banque Transatlantique SA acquired a new stake in Incyte in the 1st quarter valued at $26,000. Raiffeisen Bank International AG bought a new stake in shares of Incyte in the 4th quarter worth approximately $34,000. SVB Wealth LLC bought a new stake in Incyte in the first quarter valued at $39,000. Geneos Wealth Management Inc. boosted its stake in Incyte by 350.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 756 shares of the biopharmaceutical company's stock valued at $46,000 after purchasing an additional 588 shares during the period. Finally, WPG Advisers LLC bought a new position in Incyte in the 1st quarter worth approximately $47,000. 96.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Incyte

In related news, EVP Vijay K. Iyengar sold 1,177 shares of the company's stock in a transaction that occurred on Tuesday, July 15th. The stock was sold at an average price of $69.86, for a total value of $82,225.22. Following the sale, the executive vice president owned 35,929 shares of the company's stock, valued at approximately $2,509,999.94. This represents a 3.17% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Steven H. Stein sold 14,952 shares of the company's stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $68.47, for a total value of $1,023,763.44. Following the completion of the sale, the executive vice president directly owned 97,466 shares in the company, valued at approximately $6,673,497.02. The trade was a 13.30% decrease in their position. The disclosure for this sale can be found here. Insiders sold 52,392 shares of company stock worth $3,584,411 over the last quarter. Insiders own 17.80% of the company's stock.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.